Cost-utility analysis of mechanical thrombectomy between 6 and 24 hours in acute ischemic stroke by Pizzo, E et al.
1 
 
Article type: Research article   
Corresponding author: 
Kyriakos Lobotesis, Imaging Department, Imperial College Healthcare NHS Trust,  
Charing Cross Hospital, Fulham Palace Road, London W6 8RF, UK.  
Direct Line: 0203 311 5047, Fax: 0203 311 1861 
Email: k.lobotesis@nhs.net 
 
Cost-utility analysis of mechanical 
thrombectomy between 6 and 24 hours in 
acute ischemic stroke 
Elena Pizzo 1, Maureen Dumba 2 and Kyriakos Lobotesis 2 
1) Department of Applied Health Research, University College London, 1-19 Torrington 
Place, London WC1 E7HB, UK 
2) Imaging Department, Imperial College Healthcare NHS Trust, Charing Cross 
Hospital, Fulham Palace Road, London W6 8RF, UK 
 
Keywords 
Ischemic Stroke, Mechanical Thrombectomy, Thrombolysis, Cost-effectiveness, Cost-utility 
 
Word count:3966 
List of tables and figures 
Table 1. Base-case results. 
Figure 1. Decision models. 
Figure 2. Cost-effectiveness acceptability curves.  
Figure 3. Monte Carlo simulations of incremental cost per QALY gained of mechanical 







Recently, two randomized controlled trials demonstrated the benefit of mechanical 
thrombectomy performed between 6 and 24 hours in acute ischemic stroke.  The current 
economic evidence is supporting the intervention only within 6 hours, but extended 
thrombectomy treatment times may result in better long-term outcomes for a larger cohort 
of patients.  
Aims 
We compared the cost-utility of mechanical thrombectomy in addition to medical treatment 
versus medical treatment alone performed beyond 6 hours from stroke onset in the UK 
National Health Service (NHS).  
Methods 
A cost-utility analysis of mechanical thrombectomy compared to medical treatment was 
performed using a Markov model that estimates expected costs and quality-adjusted life 
years (QALYs) over a twenty-year time horizon. We present the results of 3 models using 
the data from the DEFUSE 3 and DAWN trials and evidence from published sources.  
Results 
Over a 20 year period, the incremental cost per QALY of mechanical thrombectomy was 
$1,564 (£1,219) when performed after 12 hours from onset, $5,253 (£4,096) after 16 hours 
and $3,712 (£2,894) after 24 hours. The probabilistic sensitivity analysis demonstrated that 
thrombectomy had a 99.9% probability of being cost-effective at the minimum willingness 
to pay for a QALY commonly used in the UK.  
Conclusions 
The results of this study demonstrate that performing mechanical thrombectomy up to 24 
hours from acute ischemic stroke symptom onset is still cost-effective, suggesting that this 
intervention should be implemented by the NHS on the basis of improvement in quality of 




Stroke is a global health issue and continues to be a leading cause of mortality and disability 
worldwide.1, 2 A number of prospective randomized trials published in 2015 showed 
mechanical thrombectomy is safe and effective in the management of ischemic stroke 
within 6 hours of symptom onset.3-7 Published evidence has shown it is also cost-
effective.8-13 The precedent to transform stroke management was therefore set. Some of the 
2015 endovascular therapy studies suggested further benefits beyond this time window. 
Specifically, REVASCAT and ESCAPE actively recruited beyond the 6-hour window with 
encouraging, but not definitive safety and efficacy outcomes.5, 6 This suggestion is now 
more certain with two prospective randomized controlled trials recently demonstrating that 
thrombectomy plus standard medical therapy for ischemic stroke at 6 to 16 hours (DEFUSE 
3) and 6 to 24 hours (DAWN) results in a better functional outcomes at 90 days than 
standard medical therapy alone.14, 15 
Previous economic evaluations of thrombectomy undertaken in the UK, have been based 
on the evidence supporting endovascular intervention only within 6 hours.8, 9 Clinical 
encounters do not always conform to these time-frames and the recent evidence shows 
extending thrombectomy treatment times may result in better long term outcomes for this 
cohort. 
Aims 
We investigated the cost-utility of mechanical thrombectomy in the acute management of 
stroke with symptom onset between 6 and 24 hours in the UK, using the results of the 
DAWN and DEFUSE 3 trials. 
Methods 
We undertook a cost-utility analysis to compare costs and outcomes of mechanical 
thrombectomy (MT) following standard medical therapy (SMT) compared to SMT alone 
in patients with acute ischemic stroke. We used the data from the DEFUSE 3 trial to 
estimate the cost-utility of MT at 16 hours, and the data from the DAWN trial to estimate 
the cost-utility of MT at 12 and 24 hours. The outcome measure was quality-adjusted life 
years (QALYs), which combine length of life and quality of life, based on National 
Institute for Health and Care Excellence (NICE) recommendations.16 The number of deaths 
averted was also reported as an additional outcome measure. The cost-effectiveness of 
mechanical thrombectomy was expressed in terms of its Incremental Cost Effectiveness 
Ratio (ICER), compared to the current medical therapy. The analysis took a UK National 
Health Service (NHS) and personal social services (PSS) perspective. Costs were 
calculated in 2017 UK£, inflated where necessary and presented in US$ using an exchange 
rate of £1= US$1.28.17-19 The time horizon was 20 years, reflecting the average life 
expectancy of the patients treated in both trials. All costs and outcomes after the first year 





We considered two treatment options: SMT alone (which includes intravenous tissue 
plasminogen activator (IV-tPA)) versus SMT followed by MT. Outcomes in both options 
were based on modified-Rankin-Scale (mRS) scores measured at 90 days after stroke, 
which were assumed to be affected by recanalization rates. 
A short-run decision analytical model (Figure 1A) was created to assess costs and clinical 
outcomes within 3 months from stroke and subsequently was utilised to distribute a 
theoretical cohort of patients into one of three possible health states. A long-run Markov 
state-transition model was then used to estimate the expected costs and outcomes over a 
lifetime horizon of 20 years using cycles of 3 months (Figure 1B). 
 
Figure 1. Decision model. 
A. Short-run analytical model (first 3 months after stroke). 
 
B. Long-run Markov model. 
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We populated the model with data from the DEFUSE 3 trial to estimate the cost-utility at 
16 hours and from the DAWN trial to estimate the cost-effectiveness at 12 and 24 hours 
(Supplementary Table I). In doing so, we took into account the different treatments 
provided and the different type of devices used for the thrombectomy and outcomes. 
 
Costs 
A micro-costing approach was used to calculate the cost of the two treatment options 
pathways. 
The cost of medical therapy was estimated to be $2,346 (£1,819), including the cost of the 
IV-tPA medication and administration (Supplementary Table II and III).20, 21 Staff time 
costs were estimated using the data on the average cost per hour.17 
The cost of the thrombectomy varied in each trial: it was estimated to be $8,320 (£6,486) 
for the DEFUSE 3 trial (where a stentriever was used in 80% of cases), and $6,339 (£4,942) 
in the DAWN trial (where a Trevo® stentriever was used for all the MT interventions). 
This includes the cost of the devices, materials and intervention (Supplementary Table III). 
The health care costs in the first 3 months after stroke and the ongoing costs in the 
following years differ according to disability (mRS score). The acute management costs 
include length of stay in the Hyper Acute Stroke Unit, in the acute High Dependency Unit, 
and in the rehabilitation ward, as well as the supported discharge cost and community care 
costs.8, 17, 21 We estimated the cost of a recurrent stroke as the mean expected cost to treat 
an average stroke that does not need SMT or MT. 
Outcomes 
Outcomes were expressed in quality-adjusted life years (QALYs), which combine length 
of life and quality of life.16 These were measured starting from the mRS score in which are 
categorized the patients affected by stroke: independent (mRS score </=2), dependent 
(mRS score 3-5) or dead (mRS=6).22 For each mRS score we used the most updated and 
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mRS 0 1 2
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reliable values available in the literature that take into account the EuroQol elicitation 
method (Supplementary Table II).21, 23-25 Other sources were used for the sensitivity 
analyses.26, 27  
Probabilities 
We used the data provided in the two trials to calculate the probability of being 
independent, dependent or dead at 90 days in each treatment arm.14, 15 For the following 
months we applied the transition probabilities in Supplementary Table II, transformed for 
cycles of 3 months. We assumed that the probability of having a recurrent stroke was the 
same for a patient coming from an independent or a dependent state. Patients could move 
between a dependent and independet state only in the first year, but thereafter they were 
assumed to remain in that state, have a recurrent stroke or die. Patients who survived 
another stroke could either die or move into a dependent state, or remain independent.23, 28 
Measuring cost-effectiveness 
Cost-effectiveness of MT plus SMT compared to SMT alone was measured in terms of the 
incremental cost per QALY gained (ICER). We also report the Net Monetary Benefits 
(NMB), calculated as the mean QALYs per patient accruing to that treatment multiplied 
by the maximum willingness to pay (WTP) for a QALY (the cost-effectiveness threshold) 
minus the mean cost per patient for the treatment. The lower and upper limit of the 
maximum willingness to pay for a QALY are $33,000 (£20,000) and $49,500 (£30,000) 
respectively in the UK.16 
Sensitivity analysis 
Extensive sensitivity analyses were performed, incuding a probabilistic sensitivity analysis 
(PSA) to determine the impact of the uncertainty surrounding the model input parameters.16 
The distributions assigned to each parameter value are described in Supplementary Table 
II. A random value from the corresponding distribution was selected. This generated an 
estimate of the mean cost and mean QALY and the NMB associated with each treatment. 
This was repeated 10,000 times and the results for each simulation were noted.  The 
proportion of times either treatment had the highest NMB was calculated for a range of 
values of the WTP for a QALY. The results are summarized using cost-effectiveness 
acceptability curves (CEACs). The mean cost, QALYs and NMB for each treatment were 
calculated from the 10,000 simulations; these are probabilistic results (Figure 3 and 
Supplementary Table IV). 
Results 
Using base case values, the thrombectomy following SMT performed within 12, 16 and 24 
hours from an acute ischemic stroke was associated with incremental costs per patient of 
$2,545 (£1,984), $8,818 (£6,875), and $8,289 (£6,463), respectively. Over 20 years, 
patients treated with MT at 12, 16 and 24 hours could gain 1.62, 1.68, and 2.23 QALYs 
respectively (Table 1). The higher cost of thrombectomy is represented by the cost of the 
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devices, materials and intervention. Thrombectomy saves more lives and those patients 
who survive are more likely to be independent (mRS 0-2), therefore the higher QALYs. 
Over 20 years, thrombectomy performed up to 24 hours after symptom onset could avert 
143 deaths over a theoretical cohort of 1000 patients (875 deaths in patients treated with 
SMT alone versus 732 deaths in patients treated with MT). 
The ICER of thrombectomy compared to SMT was $1,564 (£1,219) per QALY if 
performed within 12 hours, $5,253 (£4,095) per QALY if performed within 16 hours and 
$3,712 (£2,894) per QALY gained if performed within 24 hours (Table 1). The NMB of 
thrombectomy plus SMT was higher than the NMB of SMT alone at both the lower and 
upper limits of the maximum WTP for a QALY, indicating that this option was preferred 
on cost-effectiveness ground.  
The PSA confirms the main results (Supplementary Table IV). 
The cost-effectiveness acceptability curves for the two interventions show that mechanical 
thrombectomy had 99.9% probability of being cost-effective at the lower and upper values 
of the maximum willingness to pay for QALY commonly used in UK (Figure 2 and 3). 
The results of the one-way sensitivity analysis showed that the cost of thrombectomy must 
exceed $42,563 (£33,185) using the DEFUSE 3 trial data at 16 hours for the intervention 
to become borderline cost-effective for the lower value of the maximum willingness to pay 
for QALY. Similarly, it must exceed $45,555 (£35,518) and $55,331 (£43,140) using the 







Table 1. Base-case results: Expected values per 1,000 patients (deterministic results).  
 
Cost-utility of Mechanical Thrombectomy performed within 12 hours 




Costs $35,397,797 $37,943,267 $2,545,470 
QALYs 3,071 4,698 1,628 
ICER   $1,564 
Net Monetary Benefit    
Lower $43,367,050 $82,582,131  
Upper $82,749,474 $142,844,829  
    
Cost-utility of Mechanical Thrombectomy performed within 16 hours 




Costs $40,601,040 $49,419,626 $8,818,586 
QALYs 3,123 4,802 1,679 
ICER   $5,253 
Net Monetary Benefit    
Lower $39,516,181 $73,758,367  
Upper $79,574,792 $135,347,364  
    
Cost-utility of Mechanical Thrombectomy performed within 24 hours 
 Medical Therapy alone Mechanical Thrombectomy Difference 
Costs $34,363,561 $42,653,404 $8,289,843 
QALYs 2,322 4,555 2,233 
ICER   $3,712 
Net Monetary Benefit    
Lower $25,208,427 $74,198,857  




Figure 2. Cost-effectiveness acceptability curves showing the probability that each option 
is cost-effective at different values of the WTP for a QALY.  















Figure 3. Monte Carlo simulations of incremental cost per QALY gained of mechanical 
thrombectomy on a cohort of 1000 patients. 
 
















Previous evidence demonstrated the cost-effectiveness of mechanical thrombectomy 
compared to standard medical therapy alone within a 6 hour time-frame from symptom 
onset. This study not only validates those results, but also suggests that performing 
thrombectomy beyond this time frame and up to 24 hours after stroke symptom onset 
remains cost-effective. 
 
The 2015 publications of concordant evidence supporting the use of thrombectomy up to 
6 hours after symptom onset resulted in a paradigm shift in the modern management of 
acute stroke. Subsequently, mechanical thrombectomy is being performed more frequently, 
with decreasing costs due to economies of scale (discounts in devices purchased and more 
efficient interventions). Two of the initial seminal trials, REVASCAT and ESCAPE, 
recruited up to 8 and 12 hours respectively.5 6 This additional data was indicative that the 
6 hour mark was likely to be a conservative estimate. By combining data from the 5 big 
trials, the Highly Effective Reperfusion Evaluated in Multiple Endovascular Stroke Trials 
(HERMES) collaborative confirmed that thrombectomy was effective up to 7.3 hours after 
symptoms onset.29 DAWN and DEFUSE 3 have further added to this evidence 
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demonstrating significant benefit with thrombectomy beyond 6 hours, which was 
contributed to by the higher recanalization rate. 
 
An important point to note is the methodology was variable between trials, which makes 
the formulation of consistent inclusion criteria challenging. However, extrapolating trial 
parameters to actual population cohorts is necessary when assessing the likely impact any 
change in practice will deliver. Vanacker et al.30 showed the sub-6 hour endovascular 
intervention would benefit 10% of people presenting with acute ischemic stroke symptoms. 
Subsequently, Jadhav et al.31 applied DAWN and DEFUSE 3 criteria to a similar cohort 
and 1.7-2.7% of patients would be eligible for >6 hour MT based on these criteria. This 
suggests that despite variation in methods, an applicable inclusion model could be 
formulated. 
 
Between April 2015 and March 2016, health and social care costs related to stroke 
exceeded £1.7 billion in England, Wales and Northern Ireland.32 Despite mechanical 
thrombectomy having an initial higher cost, it leads to savings downstream in the stroke 
care pathway due to better outcomes. Between April 2016 and March 2017, 85,122 new 
cases of stroke were registered in the UK; of these 74,585 (87.6%) were ischemic strokes 
and 9,898 had thrombolysis.33 Despite 11,188 patients meeting the <6-hours eligibility for 
thrombectomy, only 580 patients (5%) were treated.33 It is not known how many of those 
remaining patients could have been treated with thrombectomy between 6 and 24 hours, 
but assuming this figure is also 5%, we estimate around 3,287 additional patients could 
have thrombectomy for an incremental budgetary impact of $8.4 million (£6.5 million) if 
performed within 12 hours, $37 million (£29 million) if performed within 16 hours, $27.2 
million (£21.2 million) if performed within 24 hours. 
 
To the best of our knowledge, this is the first study in the UK that assesses the cost-utility 
of mechanical thrombectomy performed beyond 6 hours from symptom onset. The 
advantage of this study is that we have used data from randomized controlled trials using 
thrombectomy specifically looking at the 6 to 24 hour treatment window. These studies 
focused on anterior circulation events. There remains a paucity of randomized controlled 
trial evidence looking at posterior circulation events. 
 
The analysis has some limitations. In the DEFUSE 3 trial, patients were treated with 
different devices. For this analysis, we assumed all used the SolitaireTM device, being the 
most widely accessed stentriever34 and coincidentally the most expensive device option. 
This assumption, therefore, may actually overestimate the costs of thrombectomy. We also 
assumed all patients underwent perfusion imaging in both arms. We did not include in the 
calculations the etiological main reasons of stroke (e.g. presence of hypertension, diabetes, 
atrial fibrillation or prior stroke), despite they could add to the costs, because these 
conditions were reasonably similar in both cohorts of patients. In the DAWN trial, 5% of 
patients in the intervention arm had IV-tPA compared to 13% in the control arm, therefore 
the cost has been weighted accordingly. Finally, we assumed dependent and independent 
patients have the same probability of having a recurrent stroke, although one may expect 
this probability to be higher among the more disabled. The results of our sensitivity analysis 




This study was undertaken from the perspective of the UK NHS and did not include societal 
costs. Given that the incidence of stroke in patients under 60 years of age has increased by 
more than 4% in the last three years33, it is likely that the cost savings attributable to 
mechanical thrombectomy would be greater than demonstrated if we could take into 
account productivity losses and societal costs.  
 
We have demonstrated that thrombectomy performed between 6 and 24 hours after 
symptom onset is cost-effective, based on current data. These results, combined with the 
recent trial data would make a valuable contribution to reforming acute stroke service 
models.   
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